Natco Pharma Rights Issue 2026: Price, Ratio, Dates

What Natco Pharma has announced

Natco Pharma has finalised the detailed terms of its upcoming rights issue after a Board of Directors meeting held on September 25, 2026. The company plans to raise about ₹1,279.36 crore by issuing equity shares to eligible shareholders. The rights issue price has been set at ₹750 per share for equity shares with a face value of ₹2 each. The entitlement ratio is fixed at 2 rights equity shares for every 21 fully paid-up equity shares held on the record date. Natco Pharma also disclosed the timeline for the issue, including the subscription window and the period for on-market renunciation of rights entitlements. The company’s stock exchange filings also refer to earlier steps such as in-principle approvals from the exchanges and publication of record date notices in newspapers.

Board meeting outcome and approvals

Natco Pharma informed the exchanges that its board meeting scheduled on September 25, 2026 would consider and approve various matters connected with the rights issue. These included the determination of the issue price, payment mechanism, the rights entitlement ratio, the record date, and the timing of the issue. After the meeting, the company confirmed the key terms, including the issue size and dates. The company said it had already received in-principle approvals from both BSE Limited and the National Stock Exchange of India Limited on September 21, 2026. The rights issue is also described as being within the earlier board-approved cap of up to ₹1,300 crore, which was approved on September 9, 2026, subject to regulatory approvals. Natco Pharma also referred to the draft letter of offer filed for the issue.

Key terms: price, ratio, and share count

The rights issue is priced at ₹750 per equity share, which includes a premium of ₹748 per share over the ₹2 face value. Eligible shareholders will receive rights entitlements in the ratio of 2 shares for every 21 shares held as of the record date. Natco Pharma disclosed that the issue comprises up to 1,70,58,082 fully paid-up equity shares if fully subscribed. Assuming full subscription, the company said its outstanding equity share capital would increase from 17,91,09,870 shares before the issue to 19,61,67,952 shares after the issue. The company also stated that shareholders holding fewer than 21 shares will receive zero entitlement, though they may apply for additional shares and may receive preferential allocation consideration, subject to availability. Fractional rights entitlements will be ignored while computing eligibility.

Record date and what it means for shareholders

Natco Pharma has fixed October 1, 2026 as the record date for the rights issue. This is the cut-off used to determine which shareholders are eligible to receive rights entitlements. A separate market note stated that shareholders must own Natco Pharma shares in their demat account on or before September 30, 2026 to be eligible, consistent with the October 1 record date. The company also said rights entitlements linked to disputed holdings, court proceedings, transmission cases, or demat suspense accounts will remain in abeyance until ownership is resolved before issue closure and relevant documents are submitted satisfactorily. This disclosure is relevant for shareholders whose holdings are subject to transmission, legal disputes, or other title-related issues.

Issue schedule and renunciation window

Natco Pharma said the rights issue is scheduled to open on Monday, October 12, 2026, and close on Thursday, October 22, 2026. The company has also provided for on-market renunciation of rights entitlements from October 12 to October 16, 2026. Renunciation allows eligible shareholders to renounce their entitlements on market during the specified period. Alongside the board-approved schedule, a separate note in the provided information mentioned a subscription period of September 9, 2026 to October 1, 2026, and also referenced that subscription windows are typically 15 to 30 days. However, Natco Pharma’s board-approved filing specifies the October 12 to October 22 window and the October 12 to October 16 renunciation period.

Newspaper publication of record date

Natco Pharma notified the stock exchanges that it published newspaper notices announcing the record date for the rights issue. The notices were published in Financial Express and Nava Telangana on September 26, 2026. The company said the publication was made in compliance with SEBI’s listing and disclosure regulations. It also stated that the publications are accessible on the company’s website, enabling shareholders to review the formal notice. This step is typically used to ensure wide dissemination of key dates related to corporate actions.

Use of proceeds: debt repayment and R&D

Natco Pharma’s draft letter of offer, as described in the provided material, includes planned utilisation of the proceeds. The company provided for ₹810.5 crore of debt repayment and ₹110 crore of research and development spending. The balance is earmarked for inorganic and general corporate purposes. Another note stated the fund raise is intended to provide additional financial flexibility as the company evaluates acquisitions, funds capital expenditure, and invests in its product pipeline. These planned allocations are relevant for shareholders assessing how the company intends to deploy the proceeds and how it may affect leverage and investment capacity.

Important facts at a glance

Market impact: what changes for investors

A rights issue at a stated price and ratio provides clarity on the cash call expected from eligible shareholders who want to maintain their proportionate holding. The issue price has been reported as a discount of 11% to Natco Pharma’s prevailing market price at the time of the note, though the market price itself was not specified in the provided information. If fully subscribed, the equity base increases from 17,91,09,870 shares to 19,61,67,952 shares, which changes the share count used in per-share calculations once the new shares are issued and listed. The company has also set a defined renunciation window, which enables trading of rights entitlements on market between October 12 and October 16, 2026. For shareholders with fewer than 21 shares, the disclosed “zero entitlement” position may affect participation through direct entitlement, though the company noted they may apply for additional shares.

Analysis: why the timeline and disclosures matter

The key dates and published notices reduce execution uncertainty for shareholders planning participation through ASBA or via renunciation routes. The company’s disclosure on disputed holdings and suspense accounts is material because it outlines situations where entitlements may be kept in abeyance until documentation and ownership issues are resolved. The declared use of proceeds also matters because a large portion is allocated to debt repayment (₹810.5 crore) and a defined amount to R&D (₹110 crore), which signals a mix of balance sheet and investment objectives. The rights issue size of about ₹1,279.36 crore is also close to the earlier cap of up to ₹1,300 crore approved on September 9, 2026, indicating the company has proceeded with a largely similar quantum after finalising terms. Finally, the assignment of the rights entitlement ISIN (INE987B20018) is relevant for tracking renunciation and settlement during the stated trading window.

Conclusion

Natco Pharma has set October 1, 2026 as the record date for its rights issue and finalised the key terms, including a ₹750 issue price and a 2:21 entitlement ratio. The issue is scheduled to open on October 12 and close on October 22, with renunciation on market permitted until October 16. The company has also published record date notices in Financial Express and Nava Telangana on September 26, 2026 and referenced exchange in-principle approvals received on September 21. The next operational milestones for shareholders are the record date eligibility cut-off and the subscription and renunciation windows set out in the company’s filings.